ReviewInternational journal of molecular sciences2021
Drug Discovery for
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 94 citations in OpenAlex.
- Reimagining antimicrobial resistance: AI-driven predictive epidemiology and the C-AMRE framework for next-generation antibiotic discovery.The Journal of antibiotics · 2026Review
- From Molecular Networks to Medicines: Targeting Complexity in Alzheimer's Disease (AD) Therapy.Molecular neurobiology · 2026Review
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- A meta learning and task adaptive approach for drug target affinity prediction.Nature communications · 2026Article
- Highly Drug-Resistant Escherichia coli from Hospital Wastewater with Several Evolutionary Mutations: An Integrated Insights from Molecular, Computational, and Biophysics.Molecular biotechnology · 2026Article
- Article
- Microbial-Derived Anti-Cancer Compounds: Advances in Drug Discovery, Bioengineering, and Therapeutic Applications.Anti-cancer agents in medicinal chemistry · 2026Review
- Development of machine learning models to identify potentially active compounds against tuberculosis.Scientific reports · 2025Article
- Article
- Recent advancements in drug development for pulmonary tuberculosis.Archives of microbiology · 2025Review
- Unlocking potent anti-tuberculosis natural products through structure-activity relationship analysis.Natural products and bioprospecting · 2025Review
- Integration of AI and ML in Tuberculosis (TB) Management: From Diagnosis to Drug Discovery.Diseases (Basel, Switzerland) · 2025Review
- Virtual Screening of Novel Benzothiozinone Derivatives to Predict Potential Inhibitors of Mycobacterium Tuberculosis Kinases 2D-QSAR, Molecular Docking, MM-PBSA Dynamics Simulations, and ADMET Properties.International journal of molecular sciences · 2025Article
- Coumarin hybrids: dual-target candidates for future antimicrobial and antitubercular therapies.Future medicinal chemistry · 2025Article
- Discovery and biological characterization of a novel mesoionic insecticide fenmezoditiaz.Pest management science · 2025Article
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Fritillaria steroidal alkaloids and their multi-target therapeutic mechanisms: insights from network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Unveiling the properties of ascorbic acid against M. tb through in silico approach: A comparative drug-based study.Journal of molecular modeling · 2025Article
- Dual modality feature fused neural network integrating binding site information for drug target affinity prediction.NPJ digital medicine · 2025Article
- Tuberculosis vaccines and therapeutic drug: challenges and future directions.Molecular biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Developing new, more effective antibiotics against resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.